Induction of tolerance for skin allotransplantation requires selective suppression of the host response to foreign histocompatibility antigens. This report describes a new approach which employs pre-treatment with 8-methoxypsoralen (8-MOP) and ultraviolet A light (UVA) to render the effector cells of graft rejection immunogenic for the syngeneic recipient. Eight days after BALB/c mice received CBA/j skin grafts, their splenocytes were treated with 100 ng/ml 8-MOP and 1 J/cm2 UVA prior to reinfusion into naive BALB/c recipients. Recipient mice were tested for tolerance to alloantigens in mixed leukocyte culture (MLC), cytotoxicity (CTL), delayed-type hypersensitivity assays (DTH), and challenge with a fresh CBA/j graft.
The capacity selectively to down-regulate aberrant T-cell populations is an important goal of immunotherapy. Efforts in that direction have been made in a laboratory model of autoreactive disease in which cloned anti-myelin basic protein T cells induce experimental autoimmune encephalomyelitis (EAE) in susceptible strains of rodents [I] . Cohen et al. [2, 3] have shown that, if these pathogenic cloned T cells are extracorporeally inactivated with methods that alter membrane fluidity (such as hydrostatic pressure) and then intravenously reinfused, they can immunoprotect syngeneic animals in a clonotypic manner against the same autoreactive disease.
Among the obstacles that currently preclude application of that approach to treatment of human diseases reflecting increased numbers or activity of pathogenic T cells are the difficulty in isolation, in vitro expansion, and in identifying such aberrant clones. Finally, it would be necessary that the mode of cell treatment be less systemically toxic than standard therapies currently available. Recently, we have reported that cutaneous T-cell lymphoma (CTCL) patients who received intravenous reinfusion of mononuclear cells which have been extracorporeally exposed to 8-methoxypsoralen in the presence of ultraviolet A light (UVA), demonstrated a profound and prolonged clinical response which appears to be immunologically mediated [4] . It is noteworthy that systemic toxicity was quite limited. If it can be demonstrated that this clinically practical therapy leads to a specific regulatory T-cell response, a potentially significant therapeutic principle may have been recognized: unfractionated populations of autologous mononuclear cells containing an expanded clone(s) of pathogenic T cells can immunize against the activity of the same clone(s) if extracorporeally altered in an appropriate fashion.
After the introduction of a histoincompatible tissue transplant, populations of delayed-type hypersensitivity (Tdth) and cytotoxic effector T cells (Tc) are expanded, antibody directed against the graft antigens is produced. This immune response leads to the destruction and rejection of the transplanted tissue [5] . Class I and Class II cell-surface molecules encoded by genes within the major histocompatibility complex serve as the main targets of allogeneic responses between genetically unrelated individuals [6] . Tdth responses are largely directed at Class II antigens [7] , and Tc are mainly directed at Class I molecules [8] . The antigen-binding receptor for target Class I and 11 molecules is the relevant T-cell receptor (TCR) [9] .
Prolonged survival of skin allografts is difficult to achieve due to the particularly vigorous host immune response to histoincompatible antigens associated with this organ. Therefore, the efficacy of protocols intended to inhibit the effector T cells mediating rejection of skin allografts can be demonstrated in this sensitive system. Andersson, Binz, and Wigzell [10] The following experiments were conducted to determine whether pre-exposure of BALB/c mice immune system to splenocytes obtained from other BALB/c mice, undergoing rejection of CBA/j skin grafts and inactivated with 8-MOP photoactivated by UVA light, would render the syngeneic recipients unresponsive to the CBA/j alloantigens as tested by in vitro and in vivo assays, which correlate with allograft rejection. In this report, we show that pre-exposure of the mouse immune system to cells generated during skin transplant rejection and photoinactivated with 8-MOP and UVA can be one way to render the secondary syngeneic recipients relatively tolerant to the alloantigen carried by the original skin transplant.
MATERIALS AND METHODS

Mice
BALB/cBYJ (H-2d, Mlsb), CBA/j (H-2k, Mlsd), and C57BL/10 (H-2b, Mlsb) mice were purchased from The Jackson Laboratory, Bar Harbor, ME. All mice were maintained in a specific pathogen-free facility. Female CBA/j mice four to six weeks of age were used as skin transplant donors. Female BALB/c mice four to six weeks of age were the skin transplant recipients. C57BL/10 (H-2b, Mlsb) female mice were the donors of splenocytes used as the irrelevant alloantigen control in in vitro and in vivo experiments.
Skin Transplantation and Preparation of Cell Suspension
The skin grafting was performed following the procedure of Billigham and Medawar [14] . The truncal skin of donor mice (CBA/j) was shaved and the animals were sacrificed. Full-thickness skin was obtained by sharp dissection of truncal skin, followed by removal of fat and panniculus carnosus by blunt dissection. Skin graft recipient mice (BALB/c) were shaved and anesthetized intramuscularly with .01 ml of Ketamine hydrochloride (100 mg/ml), diluted 10:1 with Xylasine (20 mg/ml). A circular piece of skin measuring approximately 1 x 1 cm was removed from each recipient mouse down to fascia from the grafting site. The grafts were applied to the fascia and sutured with Vycril 3-0 suture (Ethicon, Johnson & Johnson Co., Somerville, NJ). Rejection was allowed to take place. Eight, 12, and 15 days after transplant, spleens were removed from the mice undergoing allograft rejection. Single-cell suspensions were prepared, and red cells were lysed with 0.83 percent NH4Cl. After two washings, cells were adjusted to the appropriate concentration in phosphate saline buffer (PBS) for injections (see immunization protocol) or media (culture media consisting of RPMI 1640 supplemented with 20 mM Hepes buffer, 2 mM glutamine, 5 percent heat-inactivated fetal calf serum (FCS) (all from Gibco, Grand Island, NY), 5 x 10-5 M 2-mercaptoethanol, 100,ug/ml streptomycin, and 100 U/ml penicillin for assays (see MLC, Cytotoxicity Assay, and so on). The cell suspension was 89 percent viable as determined by trypan blue exclusion. Mean spleen cell yield was calculated for all splenocytes obtained from BALB/c mice undergoing CBA/j skin allograft rejection, and cytotoxicity assays were performed at the different time intervals mentioned (see cytotoxicity assay). Degree of rejection was defined as the product of mean cell yield and the highest cytotoxic response obtained. By this definition, the peak of rejection was considered to be eight days post-transplant.
Splenocytes obtained from these transplanted (sensitized) mice served as a source of the immunizing population of cells.
Photoinactivation
Optimal conditions for murine splenocyte photoinactivation, as determined by their proliferative response to nonspecific mitogens, has been reported elsewhere [13] . 8-MOP (Elder Pharmaceutical, Costa Mesa, CA) was dissolved in 100 percent ethanol and subsequently in PBS. Splenocytes from BALB/c mice rejecting CBA/j skin graft were incubated in 100 ng/ml of 8-MOP in shielded tubes for 20 minutes. The cell suspension was dispensed into Petri dishes (Falcon, Becton Dickinson & Co., Oxnard, CA) and exposed to 1 j/cm2 of UVA. The irradiation unit consisted of six black light bulb fluorescent tubes (40 Sylvania), emitting broad-band UVA energy (320-400 nm). Emission in the UVB range was filtered out by a sheet of window glass. Light dose was monitored by a photometer (International Light, IL 700A), equipped with a UVA probe. The cell suspension was aseptically collected and washed twice with PBS to remove the excess 8-MOP.
Immunization Protocol
Recipient mice were injected intravenously in the tail vein with 200 ,ul of PBS containing 30-50 x 1o6 cells. Among these cells was the in vivo expanded population of photoinactivated effector T (PET) cells mediating CBA/j skin allograft rejection. BALB/c recipients were injected once every week for three months. Recipient mice were then tested for T-cell unresponsiveness to CBA/j alloantigens in mixed leukocyte culture (MLC), cytotoxicity (CTL), and delayed-type hypersensitivity (DTH) assays and challenged with fresh CBA/j skin transplants.
MLC
MLC responses were performed following modifications of the methods of Rock et al. [1 5] and Kruisbeek et al. [16] and represent the in vitro proliferative response to histoincompatible Class 11 alloantigens [17] . Erythrocyte-free X-irradiated (1,800 rads) skin donor stimulator splenocytes (CBA/j) were suspended in media and aliquoted at a concentration of 2 x 105 cells/well in a volume of 50 ,l. Increasing Cytotoxicity assays were performed to detect the presence of alloreactive cells primarily responsive to Class I alloantigen disparity [8] . Skin graft recipient, naive, and PET-treated BALB/c mice were sacrificed, and a mononuclear cell suspension of spleen cells was prepared. Splenocytes from graft recipient mice were restimulated in vitro, following the methods of Buracoff et al. [19] and Granstein et al. [20] . Briefly, 8x 106 responder spleen cells were co-cultured with 3 x 106 erythrocyte-free 8-MOP-/UVA-inactivated skin donor strain (CBA/j) splenocytes in 24-well, flatbottomed microtiter plates (Falcon). Cultures were incubated for five days at 370C in a humidified atmosphere containing 5 Delayed-Type Hypersensitivity Response DTH assay was performed following the methods of Granstein et al. [20] and Van der Kwast et al. [21] and represent in vivo allogenic responses to histoincompatible Class II alloantigens [7] . Spleen cell suspension from CBA/j mice (30-50 x 106 X-irradiated splenocytes) were injected in the flank of five naive BALB/c mice (positive control group), five PET-treated BALB/c mice (experimental group 1), and five BALB/c mice treated with photoinactivated naive splenocytes (experimental group 2). For elicitation, the previously immunized groups of mice as well as five naive BALB/c mice (negative control group) received 10 x 106 CBA/j splenocytes injected subcutaneously in the right hind footpad in 0.20 ml of PBS. After 24 hours, both hind footpads were measured for thickness with a dial caliper (Monostat, Swiss-made Fisher Scientific, Springfield, NJ). The thickness of the left footpad (noninjected) was subtracted from the right (injected) footpad to measure the DTH response. Percentage of suppression was calculated by the formula: 1 -(E-N/P-N) x 100, where E is the measurement obtained from the experimental group of mice, N is the negative control, and P is the positive control. Specific suppression of the DTH response was determined by immunizing and challenging analogous groups of mice with splenocytes from C57BI/10 mice (H-2b). Statistical Analysis Statistical significance was determined according to student's t test. A p value of less than 0.05 was considered significant. RESULTS Specific Suppression of MLC BALB/c female mice, immunized with syngeneic PET cells, demonstrated a highly significant (p < 0.001) autologous response (Table 1 ) at all numbers of responder cells tested and also showed a highly significant hyporesponsiveness to H-2k, Mlsd alloantigen in MLC, when compared to the proliferative response of splenocytes obtained from either naive (Fig. la) PET-treated BALB/c mice were exposed in MLC to H-2b, Mlsb, however, an irrelevant alloantigen, the proliferative response was comparable to that of splenocytes from sensitized BALB/c mice (Fig. 1 b) . Therefore, specific hypoproliferative response in MLC to the relevant MHC antigens could be induced by immunization with PET cells. Thus, this specific hyporesponsiveness could be the result of deletion of the effector cell population mediating the recognition of the target alloantigen or inhibition of the effector cells mediated by a suppressive cell population in the spleens of PET-treated mice. Therefore, a three-party MLC was performed to determine whether the MLC hyporesponsiveness resulted from a deletion of the effector cell population or whether an inhibitory cell population had been generated (Fig. ic, id) . As anticipated, when splenocytes from sensitized BALB/c mice were admixed equally (1:1 ) with splenocytes from naive BALB/c mice and then stimulated with CBA/j, an augmented proliferative response, over that of naive BALB/c cells alone, was obtained. When cells from naive mice, however, the proliferative response was markedly suppressed (>100 percent) (p < 0.001 ) (Fig. Ic) . Similar results were obtained after admixing the splenocytes from PET-treated mice with the cells from sensitized mice (p < 0.001) (Fig. Id) . When splenocytes from sensitized and PET-treated mice were admixed and exposed to X-irradiated cells bearing the irrelevant antigen H-2b, Mlsb, however, some suppression was observed (lowest p value, <0.02) but not to the extent of the suppression demonstrated to the H-2k, Mlsd alloantigen (p < 0.001) (Fig. I e) . Therefore, the diminution of MLC reactivity against donor antigens in splenocytes from PET-treated mice resulted from the presence of a specific inhibitory cell population. Suppression of Cytotoxicity To evaluate the capacity to generate cytotoxic T cells from the spleens of PET-treated BALB/c mice, 5'Cr-labeled CBA/j or BALB/c lymphoblasts were added to an established BALB/c versus CBA/j MLC assay (Fig. 2) . Although a maximal specific cytotoxic T-cell response of 30 percent was obtained at 80:1 E:T ratio from PET-treated BALB/c mice to 5'Cr-labeled CBA/j targets, this response was significantly less than that observed in naive BALB/c splenocytes at 20, 40, and 80:1 E:T ratio (p < 0.02, <0.005, and <0.005, respectively) to identical 5'Cr-labeled CBA/j targets. Also, the specific cytotoxic T-cell response observed in spleen cells from PET-treated BALB/c mice was significantly less than that of sensitized BALB/c mice at 10, 20, and 80:1 E:T ratio (p < 0.005, <0.001, and <0.001, respectively) (Fig. 2a) . There was less than 25 percent cytotoxic response elicited from the spleens of naive, sensitized, or PET-treated mice to BALB/c 5'Cr-labeled target cells (Fig. 2b) presented by the skin graft can be observed in the spleen cells of PET-treated mice. Thus, a three-party 5'Cr-release assay was performed to determine whether the diminished cytotoxic response to CBA/j alloantigen from the spleens of PET-treated BALB/c mice was the result of an inhibitory cell population or the deletion of the effector T-cell population (Fig. 3) . First, splenocytes from naive BALB/c mice were admixed at a 1:1 ratio with cells from the PET-treated BALB/c mice and then incubated with CBA/j stimulators. The subsequent addition of 5'Cr-labeled CBA/j target lymphoblasts revealed a significant suppression at 40 and 80:1 E:T ratio (p < 0.02 and <0.002, respectively) of the normally pronounced cytotoxic T-cell response of naive BALB/c mice splenocytes to the CBA/j alloantigen (Fig. 3a) . Highly significant suppression ( p < 0.005, <0.005, <0.001, and <0.001), at all E:T ratios tested, of the sensitized BALB/c cytotoxic T-cell response to CBA/j alloantigen was obtained when cells from the sensitized BALB/c mice were admixed with splenocytes from the PET-treated BALB/c mice in the presence of inactivated CBA/j splenocytes (Fig. 3b) . The minimal autologous cytotoxic response of 25 percent observed at 80:1 E:T ratio in splenocytes from naive BALB/c mice was also significantly suppressed (p < 0.002) by the addition of cells from PET-treated mice (Fig. 4a) . The autologous cytotoxic T-cell response observed in splenocytes from sensitized BALB/c mice was also suppressed (Fig. 4b ) but not to a significant level. Therefore, pre-exposure of the immune system to PET cells resulted in augmented cell-mediated inhibition of the cytotoxic T-cell response to alloantigen. Specific Inhibition of DTH DTH experiments were performed to demonstrate in vivo inhibition of the response to alloantigen (Fig. 5) . When PET-treated mice were primed on the flank and seven days after the footpad challenged with H-2k, Mlsd alloantigen bearing lymphocytes, an 86 percent suppression of the DTH response (footpad swelling) was demonstrated as compared with positive controls; however, no suppression of the DTH response was demonstrated when PET-treated mice were primed and challenged with lymphocytes bearing the unrelated antigen H2b.
When BALB/c mice treated with photoinactivated naive cells were primed in the flank and seven days after the footpad challenge with H-2k, Mlsd alloantigen-bearing lymphocytes, however, no suppression of DTH response (footpad swelling) was demonstrated as compared with controls (Fig. 6) . 
Allograft Retention
Finally, BALB/c mice which had been repeatedly infused with PET cells recognizing the H-2k, Mlsd (CBA/j) alloantigen were challenged with a fresh CBA/j skin transplant, the survival of which was visually and histopathologically followed. Six PET-treated BALB/c female mice received CBA/j skin transplants, in parallel with naive BALB/c female mice which also received identical skin grafts. Treated mice continued to receive intravenous PET infusions on a weekly basis, following engraftment.
All control naive BALB/c mice demonstrated evidence of rejection by seven days after transplant. In contrast, none of the PET-treated mice demonstrated any visual evidence of rejection. Three PET-treated mice were sacrificed 18 days post-transplantation. Their skin grafts did not show visual evidence of rejection at that time, whereas 100 percent of the control mice transplants had already completely necrosed.
The surviving PET-treated mice were sacrificed at subsequent intervals for histological evaluation of the graft. Although these mice did not demonstrate clear visual evidence of rejection by the end of the third and seventh weeks, respectively, the histopathology evaluation performed at the third week post-transplantation revealed epidermotropism of mononuclear inflammatory cells within a viable epidermis. Confluent and focal vacuolar epidermal basal cell degeneration and focal areas of mononuclear cell infiltration of engrafted epidermis with a denser dermal mononuclear cell infiltrate were seen in the pathological specimens obtained from the fifth and seventh week post-engraftment. Four BALB/c mice, however, which had received similar amounts of photoinactivated splenocytes from syngeneic mice rejecting a CBA/j skin graft, then received a skin graft from B1O mice, which was rejected within seven days post-engraftment. The histologic evaluation of these skin grafts revealed separation of a necrotic epidermis from the dermis, which contained a very dense mononuclear cell infiltrate and thrombi formation within dermal vessels.
Therefore, pre-exposure of the mouse immune system to PET cells generated during skin transplant rejection rendered the secondary syngeneic recipient relatively, but not [5] , which have been identified as LytI +2+ [15] and L3T4+ positive [22] .
In our study, CBA/j mice (H-2k, Mlsd) were selected as skin transplant donors because of their disparity in the H-2 locus with BALB/c (H-2d, Misb) and their stimulatory phenotype in the Mls locus, theoretically maximizing the expansion of effector cells. The Mls locus is of interest because it is the only known genetic locus other than the MHC in which strong proliferative response is observed between unprimed individuals displaying disparity on it [23] . The simplest view of the Mls system at present is that it is composed of a silent allele (Mlsb) and two independent stimulatory alleles (Mls-a and c) [24] In this report, we describe a method of inducing tolerance that may be practical even in a clinical setting. In our studies, the host selects the appropriate immunoreactive cell type from a mixed splenocyte pool which includes an expanded population of effector BALB/c anti CBA/j lymphocytes. These anti H-2k, MISd lymphocytes would be the cells most likely to induce a response in the secondary recipient naive BALB/c mice, on a mere numerical basis. Moreover, Ben-Nun and Cohen [30] have demonstrated that the induction of a suppressive clonotypic response is more efficiently attained if the EAE-inducive T-cell clones used for vaccination have been activated in vitro with the antigen and attenuated either with X-irradiation or mytomicin C prior to reinfusion. If, however, viable EAE-inducing T-cell clones are intravenously infused, acute onset paralysis characteristic of EAE develops in the recipient animals. In our protocol, we have used in vivo activation by skin grafting to expand effector cells and use these cells obtained at the peak of rejection for immunization. The anti-H-2k, Mlsd T-cell-specific contribution to these results may be better ascertained after we have cloned, photoinactivated, and infused them (either alone or in varying ratios with bystander splenocytes). Under these conditions, it will also be of interest to determine whether nonspecific bystander splenocytes exert either an adjuvant or interference effect. These studies are in progress.
The identity of these cells remains to be established. It will be necessary to determine whether they are Ly2+ suppressor T cells [31] or Ly2+ anti-receptor anti-MHC cytotoxic T cells described by Kosmatopoulos et al. [32] or the CD8+ cells which specifically respond to determinants on the disease-mediating T-cell clones [33] .
In our system, photoinactivation with 8-MOP might have been so effective in maximizing the development of a specific inhibitory response to alloantigen because it reflects the ability to control two variables (drug dose and UVA energy), which limit the chemical reaction to microseconds [34] , and thus makes possible meticulous control of the dose-response curve of cellular inactivation to a level not previously attainable. Significantly, 8-MOP-UVA pre-treatment of cloned anti-basic myelin protein T cells [35] was more effective than X-irradiation of the same cells for vaccinating rats against the induction of EAE. Second, our studies on the suppression of DTH response to sheep red blood cells [36] have demonstrated that 8-MOP-UVA treatment of naive population of splenocytes is ineffective in inducing suppression, indicating that the presence of expanded population(s) of specific effector T cells are necessary. Third, Laskin et al. [37] have identified specific, saturable, high-affinity binding sites for 8-MOP on mice and human cell lines which might be a cell surface binding site that becomes covalently modified by exposure to UVA-modifying cellular antigenicity. It must be emphasized, however, that 8-MOP-UVA pre-treatment of effector cells may be merely one means of inducing the observed results.
In summary, we conclude that it is possible to induce a state of hyporeactivity against a specific set of MHC antigens. Syngeneic effector cells with specificity for these antigens can be photoinactivated and used as immunogens to induce this hyporesponsive state. Since a method for photoinactivating effector T cells in analogous fashion with that used here has been successful in the treatment of CTCL patients [4] and is currently being tested in other T-cell-mediated disorders, our protocol may have potential application in the field of transplantation in humans.
